Peptirna Therapeutics secures seed investment from Woup Partners to advance its siRNA drug delivery technology.

Target Information

Peptirna Therapeutics is a biopharmaceutical company specializing in the development of siRNA (small-interfering RNA) drug delivery systems. siRNA has emerged as a critical therapeutic modality, particularly for targeting disease-causing proteins at the RNA level, which allows for innovative approaches to treatment. Peptirna Therapeutics has created a proprietary peptide-based delivery platform known as Pepticellplex, designed to enhance the availability of siRNA to cells beyond the liver, where many current therapies are limited.

The company has made significant advancements in technologies that ensure siRNA can effectively escape the endosomes after cellular uptake, allowing for successful therapeutic action within the target cells. These advancements put Peptirna Therapeutics in a strong position within the competitive landscape of RNA-based therapies, which has historically faced challenges in delivering effective treatments.

Industry Overview

The biopharmaceutical industry in South Korea has been rapidly expanding, driven by government support and a solid foundation in biotechnology. The country aims to become one of the top five global players in biopharmaceuticals, l